• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Analysis: Disparity between number of children with major diseases and pediatric studies

Analysis: Disparity between number of children with major diseases and pediatric studies

July 23, 2012
CenterWatch Staff

New analysis shows there are major discrepancies between the amount of pediatric clinical research for several major global diseases and the number of children who suffer from those diseases. While children bear nearly 60% of the burden of 10 major global diseases, only about 12% of the clinical trials for those diseases include or focus on children, according to Boston Children's Hospital doctors Kenneth Mandl and Florence Bourgeois’s analysis of five years of clinical trial data.

The discrepancies, the authors conclude, may be related to a relative lack of industry funding and support for pediatric clinical studies. The investigators published their findings online in the journal Pediatrics.

It is well known that children and adults respond to medications differently. However, clinical research focused on adults far outstrips that on pediatric patients, creating a knowledge gap when it comes to medication efficacy and safety for children with common conditions like asthma, migraine headaches, depression and malaria.

"Children are severely underrepresented in clinical research, despite several national and global efforts aimed at addressing their medical needs," said Mandl, who, along with Bourgeois, works in Boston Children's division of emergency medicine; he also directs the intelligent health laboratory in Boston Children's informatics program. "Without proper information on pediatric safety and efficacy, doctors are often left with little choice but to extrapolate from adult studies when prescribing medications for children."

To measure the level of clinical research for diseases with a high proportion of pediatric patients, Mandl, Bourgeois and their colleagues surveyed studies registered in ClinicalTrials.gov, a database of federally and privately supported clinical trials conducted in the U.S. and around the world. The team focused on drug trials from 2006 to 2011 for the 10 highest burden conditions as listed in the World Health Organization's global burden of disease study.

The discrepancy between pediatric burden and pediatric research, while present for all 10 conditions, was most stark when looking at diseases primarily seen in middle- to low-income countries (e.g., lower respiratory infections, diarrheal disease, HIV/AIDS). The team also found that adult trials were more likely to focus on safety and to be conducted collaboratively across multiple centers than pediatric trials.

"Our study focused on the 10 conditions with the highest prevalence in the WHO data, but the discrepancy may actually be higher for those that are more rare," Bourgeois explained. "This could just be the tip of the iceberg."

Mandl and Bourgeois believe that the mechanisms for funding pediatric clinical research may contribute to the differences. More than 58% of pediatric trials they surveyed were conducted with only government or nonprofit funding, while nearly 65% of adult trials had industry funding.

"We believe industry should play a larger role in supporting and conducting clinical trials for pediatric populations, and take steps to ensure that children's needs are reflected in the clinical research enterprise,” said Mandl.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing